Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis

Prostate

Volumn 62, Issue 1, 2005, Pages 54-60

  Singh, Anu M ^a   Gagnon, Gregory ^a   Collins, Brian ^a   Niroomand Rad, Azam ^a   McRae, Donald ^a   Zhang, Ying ^b   Regan, James ^a   Lynch, John ^a   Dritschilo, Anatoly ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Conformal radiation; Dose escalation; Palladium brachytherapy

Indexed keywords

PALLADIUM 103;

AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; STATISTICAL ANALYSIS; TREATMENT FAILURE; UROGENITAL TRACT DISEASE;

AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MATCHED-PAIR ANALYSIS; NEOPLASM STAGING; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10144257195     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20118     Document Type: Article

References (23)

1. Zeitman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer: Clinical significance and therapeutic implications. Cancer 1993;71:959-969.
2. 125I implantation. Int J Radiat Oncol Biol Phys 1991;21:537-547.
3. Ragde H, Elgamal AA, Snow P, Brandt J, Bartolucci AA, Nader BS. Ten-year disease free survival after transperineal sonography guided iodine-125 brachytherapy with or without 45 Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
4. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-528.
5. Dale RG. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Br J Radiol 1989;62:241-244.
6. Dale RG. The application of the linear-quadratic model to fractionated radiotherapy when there is incomplete normal tissue recovery between fractions, and possible implications for treatments involving multiple fractions per day. Br J Radiol 1986;59:919-927.
7. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys 2000;46:165-172.
8. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-1101.
9. Duchesne GM, Peters LJ. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:747-748.
10. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmondson G. Dose escalation using confromal high dose rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-327.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-223.
13. Cox DR. Regression models and life tables. J Royal Stat Soc, Ser B, 1972;34:187-220.
14. Lehmann EL. Nonparametric: Statistical methods based on ranks. San Francisco: Holden-Day; 1975.
15. Singh A, Zelefsky MJ, Raben A, Lombardi D, Leibel SA. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Radiat Oncol Biol Phys 2000;90:275-280.
16. 103PD brachytherapy and external beam irradiation for clinically localized, high risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35:875-879.
17. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, Lichter AS. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:311-317.
18. Zagars GK, Pollack A, Von Eschenbach AC. Prognostic factors for clinically localized prostate cancer. Cancer 1997;79:1370-1380.
19. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823-832.
20. Zelefsky MJ, Leibel SA, Gaudin P, Kutchen GJ, Fleshner NE, Venkatramen ES. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
21. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;3:501-510.
22. Pollack A, Zagars GK, Smith LG, Lee J, Von Eschenbach AC, Antolak AC. Preliminary results of a randomized radiotherapy Dose-Escalation Study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-3911.
23. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling C. High dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-1116.